|
Market Closed -
NSE India S.E.
04:42:11 03/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,916.00 INR | -0.81% |
|
+0.14% | +11.41% |
| 01/09 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 01/09 | Trump announces new round of drug-pricing deals | RE |
| Market Cap | 4,59700Cr 4.86TCr 4.18TCr 3.93TCr 3.59TCr 6.71TCr 6.76TCr 46TCr 18TCr 2,34900Cr 18TCr 18TCr 7,56600Cr | P/E 2027 * |
35.4x | P/E 2028 * | 29.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4,32600Cr 4.58TCr 3.94TCr 3.7TCr 3.38TCr 6.31TCr 6.36TCr 44TCr 17TCr 2,21100Cr 17TCr 17TCr 7,12100Cr | EV / Sales 2027 * |
6.65x | EV / Sales 2028 * | 5.84x |
| Free-Float |
44.39% | Yield 2027 * |
0.89% | Yield 2028 * | 1.04% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | -0.81% | ||
| 1 week | +0.14% | ||
| Current month | -3.47% | ||
| 1 month | -2.42% | ||
| 3 months | +7.13% | ||
| 6 months | +9.45% | ||
| Current year | +11.41% |
| 1 week | 1,903.8 |  | 1,984.8 |
| 1 month | 1,868.3 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.81% | +0.14% | +21.37% | +72.78% | 4.91TCr | |
| +0.41% | +0.12% | +52.20% | +121.38% | 4.04TCr | |
| -0.97% | -3.88% | +13.37% | +84.21% | 1.22TCr | |
| -1.28% | -1.78% | -11.64% | +12.58% | 1.21TCr | |
| +0.57% | +0.95% | +29.02% | +153.11% | 914.24Cr | |
| +0.08% | -4.12% | +24.01% | +43.45% | 735.61Cr | |
| -0.04% | -0.04% | +22.68% | +222.92% | 734.89Cr | |
| +0.81% | -0.04% | +45.87% | -10.06% | 731.57Cr | |
| +0.03% | -1.75% | -40.80% | +14.39% | 518.8Cr | |
| +1.13% | -0.63% | +37.68% | +104.77% | 460.47Cr | |
| Average | -0.01% | -0.44% | +19.38% | +81.95% | 1.55TCr | |
| Weighted average by Cap. | -0.22% | +0.30% | +26.41% | +87.23% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 65TCr 688.68Cr 592.54Cr 556.05Cr 508.74Cr 949.54Cr 957.06Cr 6.58TCr 2.56TCr 33TCr 2.59TCr 2.53TCr 1,07100Cr | 73TCr 771.2Cr 663.54Cr 622.68Cr 569.7Cr 1.06TCr 1.07TCr 7.37TCr 2.87TCr 37TCr 2.9TCr 2.83TCr 1,20000Cr |
| Net income | 13TCr 137.17Cr 118.02Cr 110.75Cr 101.33Cr 189.12Cr 190.62Cr 1.31TCr 510.22Cr 6.63TCr 515.09Cr 503.85Cr 21TCr | 15TCr 162.53Cr 139.84Cr 131.23Cr 120.07Cr 224.1Cr 225.87Cr 1.55TCr 604.57Cr 7.85TCr 610.34Cr 597.03Cr 25TCr |
| Net Debt | -27TCr -286.32Cr -246.35Cr -231.18Cr -211.51Cr -394.78Cr -397.91Cr -2.73TCr -1.07TCr -14TCr -1.08TCr -1.05TCr -45TCr | -34TCr -358Cr -308.02Cr -289.05Cr -264.46Cr -493.6Cr -497.51Cr -3.42TCr -1.33TCr -17TCr -1.34TCr -1.32TCr -56TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | ₹1,916.00 | -0.81% | 12,05,188 |
| 02/26/02 | ₹1,931.70 | +0.14% | 12,45,419 |
| 01/26/01 | ₹1,929.00 | -2.81% | 35,95,272 |
| 31/26/31 | ₹1,984.80 | +3.37% | 24,13,221 |
| 28/26/28 | ₹1,920.00 | +0.35% | 11,40,742 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
